Rise and shine, everyone, another busy day is on the way. We can tell because the short people scurried off to their respective destinations faster than usual this morning. But busy is a good thing, or so they say. For those of you who may need some convincing, perhaps you would like to join us for a cup or three of stimulation. Our choice today is almond toffee, should you track this sort of thing. Meanwhile, here are a few tidbits to get you started. Once again, we wish you the best as you attempt to conquer the world. And as always, please do keep in touch. …

Lord Jim O’Neill, a former chief economist at Goldman Sachs who advised the U.K. government on antibiotic resistance, is shocked by drug makers failing to tackle drug-resistant infections and suggests the solution may be to “just take it away from them and take it over,” the BBC says. There has not been a new class of antibiotic since the 1980s. In a 2016 report, he proposed giving companies around $1 billion for each novel antibiotic developed. “There’s endless talk but there’s no progress in waking up the pharmaceutical industry to want to do this,” he says.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy